Algernon NeuroScience Appoints Validcare as CRO for Phase 2a DMT Human Stroke Trial
Validcare selected as CRO for Phase 2a clinical study examining DMT treatment in stroke patients, with equity investment aligning incentives toward timely completion and data quality.